ImmunoGen, Inc - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Detailed information on ImmunoGen, Inc required for business and competitor intelligence needs
A study of the major internal and external factors affecting ImmunoGen, Inc in the form of a SWOT analysis
An in-depth view of the business model of ImmunoGen, Inc including a breakdown and examination of key business segments
Intelligence on ImmunoGen, Inc’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about ImmunoGen, Inc, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
ImmunoGen (or ‘the company’) is a developer of targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology. The ADC technology comprises the company’s portfolio of cancer-cell killing agents that can be attached to antibodies for targeted delivery to cancer cells. ImmunoGen is headquartered in Waltham, Massachusetts, and employed 280 people as of June 30, 2013. The company recorded revenues of $35.5 million during the financial year ended June 2013 (FY2013), as compared to the revenues of $16.4 million in FY2012. The operating loss of the company was $73 million in FY2013, as compared to an operating loss of $73.3 million in FY2012. The net loss was $72.8 million in FY2013, as compared to a net loss of $73.3 million in FY2012.
Reasons to Purchase:
Gain understanding of ImmunoGen, Inc and the factors that influence its strategies
Track strategic initiatives of the company and latest corporate news and actions
Assess ImmunoGen, Inc as a prospective partner, vendor or supplier
Support sales activities by understanding your customers' businesses better
Stay up to date on ImmunoGen, Inc’s business structure, strategy and prospects